Topics
Business & Finance
-
Wednesday - May 2, 2012
Not intended for U.S. and UK media:
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) » more
-
Friday - April 27, 2012
Annual Stockholders' Meeting 2012 » more
-
Friday - April 27, 2012
Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders’ Meeting of Bayer AG:
Bayer has great potential for the future too
Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1 » more
-
Thursday - April 26, 2012
1st quarter of 2012:
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed » more
-
Wednesday - April 25, 2012
Not intended for US or UK use - Aesthetic medicine:
Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat » more
-
Friday - April 20, 2012
New fungicidal seed treatment product for oilseed rape:
First approval worldwide for EverGol™ in seed treatment
Launch in Canada planned before the end of the year » more
-
Tuesday - April 17, 2012
Not intended for U.S. and UK Media: Prevention of Venous Blood Clots after Elective Total Hip or Knee Replacement Surgery:
Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots
Outcomes from XAMOS study of more than 17,000 orthopaedic surgery patients provide further confirmation of clinical value of rivaroxaban / XAMOS reaffirms robust findings from RECORD – the world’s largest trial programme assessing oral anticoagulation in people requiring hip or knee replacement / Rivaroxaban is the world’s most prescribed new oral anticoagulant in the orthopaedic setting, with almost 2 million patients treated in this indication alone » more
-
Thursday - April 12, 2012
Innovative breeding approach creates new opportunities for sugar beet growers:
Bayer CropScience and KWS SAAT AG co-develop herbicide-tolerant sugar beet » more
-
Thursday - April 12, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE
Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE » more
-
Tuesday - April 3, 2012
Not intended for U.S. and U.K. Media
Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival » more
-
Monday - March 26, 2012
Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):
Bayer’s Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study
Rivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine » more
-
Monday - March 19, 2012
Not intended for UK and US Media: Treatment of Pulmonary Embolism (PE):
Results of the Phase III EINSTEIN-PE Study with Bayer’s Xarelto® (Rivaroxaban) to be Presented in Late-Breaking Clinical Trials Session at ACC 2012 » more
-
Wednesday - March 14, 2012
“Meet Management” investor conference:
Bayer sets ambitious targets for 2014
Good sales and earnings perspectives for HealthCare and CropScience / MaterialScience aims to build on its leading market position » more
-
Thursday - March 8, 2012
Not intended for U.S. and UK Media
EYLEA® (aflibercept) Injection approved for the Treatment of Wet Age-Related Macular Degeneration in Australia
Approval based on positive results of VIEW 1 and VIEW 2 clinical trials » more
-
Tuesday - February 28, 2012
Financial News Conference
Full Year 2011 Results » more
-
Tuesday - February 28, 2012
Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Granted Priority Review by US FDA to Prevent Secondary Cardiovascular Events in Patients with ACS » more
-
Thursday - February 23, 2012
Elections to the Supervisory Board to be held at the Annual Stockholders’ Meeting on April 27, 2012
Werner Wenning to be proposed as Chairman of the Supervisory Board of Bayer AG
Dr. Manfred Schneider to remain in office until September 30, 2012 / Two candidates nominated for election as new stockholder representatives / Stockholders to resolve on a new compensation system for the members of the Supervisory Board » more
-
Thursday - February 23, 2012
Bayer plans dividend increase for 2011 to EUR 1.65 per share
Payout to rise by 10 percent to EUR 1,364 million » more
-
Monday - February 20, 2012
Not intended for U.S. and UK Media
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye » more
-
Wednesday - January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
